Shares in Sanofi were sliding today after a double dose of bad news for its oral BTK inhibitor tolebrutinib, in development as a therapy for multiple sclerosis (MS). Along with what looks set to be ...
The biggest stories of the day delivered to your inbox.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results